These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27796774)

  • 1. Employing quality control and feedback to the EQ-5D-5L valuation protocol to improve the quality of data collection.
    Purba FD; Hunfeld JA; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Passchier J; Busschbach JJ
    Qual Life Res; 2017 May; 26(5):1197-1208. PubMed ID: 27796774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality Control Process for EQ-5D-5L Valuation Studies.
    Ramos-Goñi JM; Oppe M; Slaap B; Busschbach JJ; Stolk E
    Value Health; 2017 Mar; 20(3):466-473. PubMed ID: 28292492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.
    Oppe M; Devlin NJ; van Hout B; Krabbe PF; de Charro F
    Value Health; 2014 Jun; 17(4):445-53. PubMed ID: 24969006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
    Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
    Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol.
    Stolk E; Ludwig K; Rand K; van Hout B; Ramos-Goñi JM
    Value Health; 2019 Jan; 22(1):23-30. PubMed ID: 30661630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration.
    Finch AP; Meregaglia M; Ciani O; Roudijk B; Jommi C
    Soc Sci Med; 2022 Jan; 292():114519. PubMed ID: 34736804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How Prevalent Are Implausible EQ-5D-5L Health States and How Do They Affect Valuation? A Study Combining Quantitative and Qualitative Evidence.
    Yang Z; Feng Z; Busschbach J; Stolk E; Luo N
    Value Health; 2019 Jul; 22(7):829-836. PubMed ID: 31277831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Test-Retest Reliability of EQ-5D-5L Valuation Techniques: The Composite Time Trade-Off and Discrete Choice Experiments.
    Purba FD; Hunfeld JAM; Timman R; Iskandarsyah A; Fitriana TS; Sadarjoen SS; Passchier J; Busschbach JJV
    Value Health; 2018 Oct; 21(10):1243-1249. PubMed ID: 30314626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Handling Data Quality Issues to Estimate the Spanish EQ-5D-5L Value Set Using a Hybrid Interval Regression Approach.
    Ramos-Goñi JM; Craig BM; Oppe M; Ramallo-Fariña Y; Pinto-Prades JL; Luo N; Rivero-Arias O
    Value Health; 2018 May; 21(5):596-604. PubMed ID: 29753358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Egyptian EQ-5D-5L Extensive Pilot Study: Lessons Learned.
    Al Shabasy S; Roudijk B; Abbassi M; Finch A; Stolk E; Farid S
    Pharmacoeconomics; 2023 Mar; 41(3):329-338. PubMed ID: 36434416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EQ-5D-5L norms for the urban Chinese population in China.
    Yang Z; Busschbach J; Liu G; Luo N
    Health Qual Life Outcomes; 2018 Nov; 16(1):210. PubMed ID: 30409137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping and direct valuation: do they give equivalent EQ-5D-5L index scores?
    Luo N; Cheung YB; Ng R; Lee CF
    Health Qual Life Outcomes; 2015 Oct; 13():166. PubMed ID: 26438167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behind the Scenes: A Qualitative Investigation of Interviewers' Performance in EQ-5D Valuation Studies.
    Varriale C; Andrulli G; Meregaglia M; Rencz F; Finch AP
    Pharmacoecon Open; 2024 May; 8(3):389-401. PubMed ID: 38592657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valuing EQ-5D-5L health states 'in context' using a discrete choice experiment.
    Cole A; Shah K; Mulhern B; Feng Y; Devlin N
    Eur J Health Econ; 2018 May; 19(4):595-605. PubMed ID: 28569351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Split Version and Feedback Module on the Improvement of Time Trade-Off Data.
    Wong ELY; Shah K; Cheung AWL; Wong AYK; Visser M; Stolk E
    Value Health; 2018 Jun; 21(6):732-741. PubMed ID: 29909879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health literacy and logical inconsistencies in valuations of hypothetical health states: results from the Canadian EQ-5D-5L valuation study.
    Al Sayah F; Johnson JA; Ohinmaa A; Xie F; Bansback N;
    Qual Life Res; 2017 Jun; 26(6):1483-1492. PubMed ID: 28124280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
    van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
    Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the performance of the EQ-5D-3L and the EQ-5D-5L in young Portuguese adults.
    Ferreira LN; Ferreira PL; Ribeiro FP; Pereira LN
    Health Qual Life Outcomes; 2016 Jun; 14():89. PubMed ID: 27267761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Logical inconsistencies in time trade-off valuation of EQ-5D-5L health states: Whose fault is it?
    Yang Z; van Busschbach J; Timman R; Janssen MF; Luo N
    PLoS One; 2017; 12(9):e0184883. PubMed ID: 28934266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes.
    Oppe M; Rand-Hendriksen K; Shah K; Ramos-Goñi JM; Luo N
    Pharmacoeconomics; 2016 Oct; 34(10):993-1004. PubMed ID: 27084198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.